BSE filing, NSE: NECLIFE. Summary written from the filing by ALFA Finder's alert engine.
Nectar Lifesciences Ltd: key numbers
- Share price
- ₹10.33
- Market cap
- ₹231.7 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹-292.9 Cr
- P/E (TTM)
- -0.9×Sector 46.5×
- Promoter holding
- 51.84%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nectar Lifesciences Ltd
All →Nectar Lifesciences Other Announcement
Nectar Lifesciences Ltd has filed its quarterly shareholding pattern as per SEBI regulations. The document details the promoter group and public shareholding for the quarter.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences Limited submitted the minutes of its 31st Annual General Meeting held on September 18, 2026. Shareholders approved financial statements and the re-appointment of directors.
Nectar Lifesciences Legal & Regulatory
Nectar Lifesciences provided an update on a material tax litigation where the High Court remanded the matter to the Appellate Authority for fresh consideration.
Nectar Lifesciences Management Change
Nectar Lifesciences Limited has announced the appointment of Dr. Gunmala Suri as a Director. Additionally, three other directors have been re-appointed to the Board.
Nectar Lifesciences Annual General Meeting
Nectar Lifesciences filed proceedings of its 31st AGM held September 18, 2026. Resolutions covered adoption of FY26 financials and director re-appointments.
Nectar Lifesciences Annual Report
Nectar Lifesciences Ltd. has released its Annual Report for FY 2025-26. The 31st Annual General Meeting is scheduled for September 18, 2026, via video conferencing.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.